Thor Medical ASA (LTS:0R6Y) Retained Earnings : kr-63.06 Mil (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Thor Medical ASA Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Thor Medical ASA's retained earnings for the quarter that ended in Dec. 2024 was kr-63.06 Mil.

Thor Medical ASA's quarterly retained earnings declined from Dec. 2023 (kr-20.85 Mil) to Jun. 2024 (kr-33.90 Mil) and declined from Jun. 2024 (kr-33.90 Mil) to Dec. 2024 (kr-63.06 Mil).

Thor Medical ASA's annual retained earnings increased from Dec. 2022 (kr-25.92 Mil) to Dec. 2023 (kr-20.85 Mil) but then declined from Dec. 2023 (kr-20.85 Mil) to Dec. 2024 (kr-63.06 Mil).

Thor Medical ASA Retained Earnings Historical Data

The historical data trend for Thor Medical ASA's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Thor Medical ASA Retained Earnings Chart

Thor Medical ASA Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Retained Earnings

Get a 7-Day Free Trial

-17.15

-58.83

-25.92

-20.85

-63.06

Thor Medical ASA Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Retained Earnings	Get a 7-Day Free Trial															-25.92	-51.50	-20.85	-33.90	-63.06

Thor Medical ASA Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Thor Medical ASA (LTS:0R6Y) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Thor Medical ASA Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Thor Medical ASA (LTS:0R6Y) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

TRMED:Norway 8NN:Germany

Address

Karenslyst Alle 9C, Oslo, NOR, 0278

Website

https://www.thormedical.no

Thor Medical ASA is a Norway-based biopharmaceutical company. The Company is a producer and supplier of alpha-particle emitters for cancer therapy. The production process is based on separation of natural occurring radioactive decay products from thorium. The Company is utilizing alpha-emitters in radiotherapy and cancer treatments using Pb-212, which can be produced from naturally occurring isotope Thorium-232 and Lead-212. The Company has developed a proprietary technology for the manufacturing of radionuclides, alpha-particle emitters from natural resources. The high energy deposition and the short range of alpha particles make it possible to eradicate cancer cells while minimizing damage to nearby healthy cells.

Thor Medical ASA Headlines

No Headlines